Beta-blockers for preventing aortic dissection in Marfan syndrome.

CONCLUSIONS: Based on only one, low-quality RCT comparing long-term propranolol to no treatment in people with Marfan syndrome, we could draw no definitive conclusions for clinical practice. High-quality, randomised trials are needed to evaluate the long-term efficacy of beta-blocker treatment in people with Marfan syndrome. Future trials should report on all clinically relevant end points and adverse events to evaluate benefit versus harm of therapy. PMID: 29110304 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29110304?dopt=Abstract

Source: Cochrane Database of Systematic Reviews - November 7, 2017 Category: General Medicine Authors: Koo HK, Lawrence KA, Musini VM Tags: Cochrane Database Syst Rev Source Type: research